- Home
- WF vs RPRX Comparison
WF vs RPRX Comparison
Compare WF & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WF | RPRX |
|---|---|---|
| Founded | 1899 | 1996 |
| Country | South Korea | United States |
| Employees | N/A | 100 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.7B | 19.7B |
| IPO Year | 2003 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WF | RPRX |
|---|---|---|
| Price | $64.49 | $45.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $47.75 |
| AVG Volume (30 Days) | 85.1K | ★ 3.0M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | 1.53% | ★ 2.05% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.78 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | $17.55 | $38.30 |
| Revenue Next Year | $3.99 | $4.80 |
| P/E Ratio | ★ $9.03 | $25.79 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $29.44 | $29.66 |
| 52 Week High | $84.71 | $47.86 |
Technical Indicators
Market Signals| Indicator | WF | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.97 | 54.97 |
| Support Level | $51.38 | $44.94 |
| Resistance Level | N/A | $46.14 |
| Average True Range (ATR) | 2.43 | 0.91 |
| MACD | -1.84 | -0.24 |
| Stochastic Oscillator | 0.00 | 25.13 |
Price Performance
Historical ComparisonAbout WF Woori Financial Group Inc. (each representing three (3) shares of)
Woori Financial Group Inc is a banking and financial services holding company that offers a wide range of services, including corporate banking, consumer banking, credit card operations, investment banking, capital markets activities, international banking, asset management, and other businesses. The operating segments of the company include Banking, Credit card, Capital, Investment banking, and others.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.